Licensing Partners

LICR’s interactions with industry are guided by principles designed to both protect the ethos and integrity of the Institute, and to ensure—as much as is possible—that LICR discoveries are actively pursued as cancer diagnostic, prognostic or therapeutic agents.

Some of our licensing partners are:

  • Cambrex Bio Science Walkersville Inc. (USA) - license agreement for use of LICR's conditional immortalization technology to use on cell types critical to understand and manage metabolic disease, and to generate cell volumes sufficient for high throughput screening for drug discovery.
  • CSL Limited (Australia) - i) co-development of a therapeutic cancer vaccine combining LICR's NY-ESO-1 cancer antigen with an immune stimulant, the ISCOMATRIX™ adjuvant, from CSL Ltd with clinical trials conducted by the LICR and Cancer Research Institute in the Cancer Vaccine Collaborative;

    - ii) collaboration agreement for the development of vascular endothelial growth factor B (VEGF-B) and associated intellectual property (discovered as part of the Angiogenesis & Lymphangiogenesis Program), which has potential applications in the treatment of cancer, rheumatoid arthritis and cardiovascular disease.
  • GlaxoSmithKline - licensed a substantial portfolio of tumor-specific antigens from LICR for the development of therapeutic cancer vaccines. The licensing agreement follows a long-standing collaboration between both parties on GSK's investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI), which is phase III trials for melanoma and non-small cell lung cancer (NSCLC).
  • KaloBios (USA) - exclusively in-licensed an antibody drug candidate, derived by LICR, for the treatment of autoimmune diseases.
  • Licentia Ltd (Finland) - partnered with LICR to form the start-up company, Lymphatix Ltd, to develop vascular endothelial growth factor (VEGF)-C and VEGF-D (discovered as part of the Angiogenesis & Lymphangiogenesis Program) in gene transfer vectors that modulate the growth and function of blood and lymphatic vessels to indications with impaired blood supply to tissues.
  • Morphotek Inc.(USA) - collaborative research and development agreement to develop LICR's monoclonal antibodies (mAbs), and cell lines producing humanized mAbs that specifically target cell surface cancer antigens for the treatment of cancer and other diseases.
  • Wilex (Germany) - research and development agreement to develop the G250 monoclonal antibody for two clinical applications—a therapy and a diagnostic agent—for kidney (clear cell renal) cancer with LICR sponsoring and conducting early-phase clinical trials.
Bookmark and Share